Heptares Therapeutics
Elizabeth Stanley has a diverse work experience in the field of scientific research and analysis. Elizabeth is currently employed as a Senior Informatics Scientist at Sosei Heptares since September 2022. Prior to this, they worked at RXCELERATE LIMITED as a Systems Biology Lead from May 2018 to June 2022. Before that, Elizabeth was a Bioanalyst at Total Scientific Ltd from March 2016 to April 2018. Elizabeth also served as a Scientific Investigator at the Medical Research Council - HNR from January 2012 to December 2015. Elizabeth's early career included a role as a Research Associate at Imperial College London from 2002 to 2004.
Elizabeth Stanley earned a Bachelor of Science (BSc) degree in Chemistry from the University of Birmingham, which they completed between 1995 and 1998. Following this, they pursued a Ph.D. in Chemistry at Imperial College London from 1999 to 2002. In March 2021, Elizabeth obtained certification as a Member of the Royal Society of Chemistry from the Royal Society of Chemistry.
This person is not in any teams
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.